San Diego, CA – July 15th, 2013 – Avineuro Pharmaceuticals, Inc. announced today an initiation of Phase 2b clinical studies of AVN-211, the best in-class, selective small molecule antagonist of 5-HT6 receptor for treatment of Schizophrenia. Earlier Avineuro Pharmaceuticals, Inc. reported positive top-line results from a Phase 2a clinical trial in schizophrenia patients stabilized on antipsychotic treatment (CNS Spectrums, July 11 2013: Avineuro Pharmaceuticals, Inc. expects market authorization in 2015 and plans to start additional clinical trials with AVN-211 in Alzheimer’s disease next year.
About AVN-211: AVN-211 is a novel highly selective, the best in class, 5-HT6 receptor antagonist discovered and optimized on the company’s drug discovery 5-HT6 platform.

About Cognition impairment in Schizophrenia:
Cognition impairment in patients with schizophrenia is recognized by many psychiatrists as the very core of the dysfunction in this disease making it extremely difficult for patients to work, study and maintain a social lifestyle.
About Avineuro Pharmaceuticals, Inc.: Avineuro discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Avineuro emphasizes a rational approach to drug discovery that combines modern medicinal chemistry with streamlined pre-clinical and clinical development studies, thus allowing a fast transition to proof-of-concept product candidates.

Alena Ivachtchenko, MBA Director of Business Development
Avineuro Pharmaceuticals, Inc.
6605 Nancy Ridge Drive
San Diego, CA 92121
Phone: 1-858-357-6627